Altimmune Inc (ALT)
6.47
-0.34
(-4.99%)
USD |
NASDAQ |
Sep 27, 16:00
6.49
+0.02
(+0.31%)
After-Hours: 20:00
Altimmune SG&A Expense (TTM): 19.75M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 19.75M |
March 31, 2024 | 18.92M |
December 31, 2023 | 18.14M |
September 30, 2023 | 17.61M |
June 30, 2023 | 17.59M |
March 31, 2023 | 17.24M |
December 31, 2022 | 17.13M |
September 30, 2022 | 17.11M |
June 30, 2022 | 16.77M |
March 31, 2022 | 16.02M |
December 31, 2021 | 15.41M |
September 30, 2021 | 15.75M |
June 30, 2021 | 15.81M |
March 31, 2021 | 14.70M |
December 31, 2020 | 13.21M |
September 30, 2020 | 11.11M |
June 30, 2020 | 9.080M |
March 31, 2020 | 8.766M |
December 31, 2019 | 8.501M |
September 30, 2019 | 8.906M |
June 30, 2019 | 8.682M |
March 31, 2019 | 9.384M |
December 31, 2018 | 9.766M |
September 30, 2018 | 8.939M |
June 30, 2018 | 10.01M |
Date | Value |
---|---|
March 31, 2018 | 8.875M |
December 31, 2017 | 8.458M |
September 30, 2017 | 8.669M |
June 30, 2017 | 8.920M |
March 31, 2017 | 8.092M |
December 31, 2016 | 7.254M |
September 30, 2016 | 6.425M |
June 30, 2016 | 4.367M |
March 31, 2016 | 5.219M |
December 31, 2015 | 6.222M |
September 30, 2015 | 7.868M |
June 30, 2015 | 9.830M |
March 31, 2015 | 10.43M |
December 31, 2014 | 10.91M |
September 30, 2014 | 12.87M |
June 30, 2014 | 13.76M |
March 31, 2014 | 13.68M |
December 31, 2013 | 13.28M |
September 30, 2013 | 11.32M |
June 30, 2013 | 10.51M |
March 31, 2013 | 10.96M |
December 31, 2012 | 11.63M |
September 30, 2012 | 11.68M |
June 30, 2012 | 11.69M |
March 31, 2012 | 12.32M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
8.501M
Minimum
Dec 2019
19.75M
Maximum
Jun 2024
14.88M
Average
15.92M
Median
SG&A Expense (TTM) Benchmarks
Eli Lilly and Co | 7.106B |
Viking Therapeutics Inc | 37.92M |
Amgen Inc | 7.22B |
Pfizer Inc | 15.07B |
Avid Bioservices Inc | 27.90M |